Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tg Therapeutics (TGTX)

Tg Therapeutics (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,479,249
  • Shares Outstanding, K 159,688
  • Annual Sales, $ 616,290 K
  • Annual Income, $ 447,180 K
  • EBIT $ 123 M
  • EBITDA $ 121 M
  • 60-Month Beta 1.87
  • Price/Sales 7.58
  • Price/Cash Flow 10.45
  • Price/Book 7.17

Options Overview Details

View History
  • Implied Volatility 58.46% (+4.03%)
  • Historical Volatility 35.55%
  • IV Percentile 35%
  • IV Rank 25.14%
  • IV High 111.36% on 07/10/25
  • IV Low 40.70% on 01/21/26
  • Expected Move (DTE 8) 1.56 (5.76%)
  • Put/Call Vol Ratio 0.13
  • Today's Volume 2,986
  • Volume Avg (30-Day) 1,694
  • Put/Call OI Ratio 0.47
  • Today's Open Interest 64,434
  • Open Int (30-Day) 62,239
  • Expected Range 25.45 to 28.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.25
  • Number of Estimates 4
  • High Estimate 0.37
  • Low Estimate 0.12
  • Prior Year 0.03
  • Growth Rate Est. (year over year) +733.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.76 +0.86%
on 03/12/26
31.34 -13.89%
on 02/26/26
-1.43 (-5.03%)
since 02/12/26
3-Month
26.76 +0.86%
on 03/12/26
33.24 -18.80%
on 01/14/26
-4.36 (-13.91%)
since 12/12/25
52-Week
25.28 +6.76%
on 08/11/25
46.48 -41.93%
on 05/01/25
-10.24 (-27.50%)
since 03/12/25

Most Recent Stories

More News
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update

- PBGENE-HBV Phase 1 data featured Late Breaker presentation at AASLD, The Liver Meeting, showing safety, tolerability and cumulative, dose-dependent antiviral activity - ...

TGTX : 26.83 (-4.35%)
DTIL : 5.57 (+10.08%)
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis

NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of data from a post hoc pooled analysis of the Phase 3 ULTIMATE I and II studies evaluating...

TGTX : 26.83 (-4.35%)
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting

NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with...

TGTX : 26.83 (-4.35%)
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis

– Milestone payments include $5.25 million cash and $2.25 million purchase of Precision stock – – Cash received supports Precision’s expected cash runway through...

TGTX : 26.83 (-4.35%)
DTIL : 5.57 (+10.08%)
TG Therapeutics: Q4 Earnings Snapshot

TG Therapeutics: Q4 Earnings Snapshot

TGTX : 26.83 (-4.35%)
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance

Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively Target guidance of approximately...

TGTX : 26.83 (-4.35%)
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Thursday, February 26, 2026, at 8:30 AM ET to discuss results for...

TGTX : 26.83 (-4.35%)
Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis

During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained consistent...

TGTX : 26.83 (-4.35%)
TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis

A Media Snippet accompanying this announcement is available by clicking on this link. NEW YORK, Feb. 08, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced a collaboration...

TGTX : 26.83 (-4.35%)
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ®  (ublituximab-xiiy), to be presented at the Americas...

TGTX : 26.83 (-4.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various...

See More

Key Turning Points

3rd Resistance Point 29.99
2nd Resistance Point 29.54
1st Resistance Point 28.79
Last Price 26.83
1st Support Level 27.59
2nd Support Level 27.14
3rd Support Level 26.39

See More

52-Week High 46.48
Fibonacci 61.8% 38.38
Fibonacci 50% 35.88
Fibonacci 38.2% 33.38
Last Price 26.83
52-Week Low 25.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar